Gowthami Morey Arepally, MD

Associate Professor of Medicine
Associate Professor of Pathology
Campus mail Duke Box 3486, Durham, NC 27710
Phone (919) 668-3696
Email address arepa001@mc.duke.edu

Gowthami M. Arepally, M.D. is an Associate Professor in the Division of Hematology at Duke University Medical Center and the Medical Director of Therapeutic Apheresis at Duke.  Her clinical interests are in immune thrombocytopenias, thrombotic disorders, and applications of therapeutic apheresis for immunologic disorders.    Dr. Arepally’s long-standing research program investigates immunoregulatory mechanisms in HIT.  Current laboratory efforts focus on the role of complement activation in the immune pathogenesis of HIT, investigations of protamine/heparin antibodies and development of murine models for studies of the HIT immune response.  Clinical projects include applications of therapeutic apheresis, including development of a multi-site network for investigations of thrombotic microangiopathy, studies of therapeutic plasma exchange for HIT and solid organ transplantation. 

Education and Training

  • Fellow in Hematology-Oncology, Medicine, University of Pennsylvania, 1993 - 1997
  • Chief Medical Resident, Medicine, Emory University, 1992 - 1993
  • Medical Resident, Medicine, Emory University, 1989 - 1992
  • M.D., Vanderbilt University, 1989

Publications

Snyder, LD, Gray, AL, Reynolds, JM, Arepally, GM, Bedoya, A, Hartwig, MG, Davis, RD, Lopes, KE, Wegner, WE, Chen, DF, and Palmer, SM. "Antibody desensitization therapy in highly sensitized lung transplant candidates." American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 14, no. 4 (April 2014): 849-856.

PMID
24666831
Full Text

Snyder, LD, Gray, AL, Reynolds, JM, Arepally, GM, Bedoya, A, Hartwig, MG, Davis, RD, Lopes, KE, Wegner, WE, Chen, DF, and Palmer, SM. "Antibody desensitization therapy in highly sensitized lung transplant candidates." American Journal of Transplantation 14, no. 4 (January 1, 2014): 849-856.

Full Text

Cuker, A, Cines, DB, and Arepally, G. "Autoantibodies in Heparin-Induced Thrombocytopenia." (December 1, 2013): 511-518. (Chapter)

Full Text

Litvinov, RI, Yarovoi, SV, Rauova, L, Barsegov, V, Sachais, BS, Rux, AH, Hinds, JL, Arepally, GM, Cines, DB, and Weisel, JW. "Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4." J Biol Chem 288, no. 46 (November 15, 2013): 33060-33070.

PMID
24097975
Full Text

Cuker, A, Rux, AH, Hinds, JL, Dela Cruz, M, Yarovoi, SV, Brown, IAM, Yang, W, Konkle, BA, Arepally, GM, Watson, SP, Cines, DB, and Sachais, BS. "Novel diagnostic assays for heparin-induced thrombocytopenia." Blood 121, no. 18 (May 2, 2013): 3727-3732.

PMID
23446735
Full Text

Cuker, A, Rux, AH, Hinds, JL, Dela Cruz, M, Yarovoi, SV, Brown, IAM, Yang, W, Konkle, BA, Arepally, GM, Watson, SP, Cines, DB, and Sachais, BS. "Novel diagnostic assays for heparin-induced thrombocytopenia." BLOOD 121, no. 18 (May 2, 2013): 3727-3732.

Full Text

Lee, GM, Welsby, IJ, Phillips-Bute, B, Ortel, TL, and Arepally, GM. "High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass." Blood 121, no. 15 (April 11, 2013): 2828-2835.

PMID
23422751
Full Text

Lee, GM, and Arepally, GM. "Heparin-induced thrombocytopenia." Hematology Am Soc Hematol Educ Program 2013 (2013): 668-674. (Review)

PMID
24319250
Full Text

Lee, GM, and Arepally, GM. "Diagnosis and Management of Heparin-Induced Thrombocytopenia." Hematology/Oncology Clinics of North America (2013).

PMID
23714311
Full Text

Lee, GM, and Arepally, GM. "Diagnosis and management of heparin-induced thrombocytopenia." Hematology/Oncology Clinics of North America 27, no. 3 (2013): 541-563.

Full Text

Pages